Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valproate to Attenuate the Progression of Alzheimer's Disease
NCT00071721Phase 3Completed
- Sponsor
- Alzheimer's Disease Cooperative Study
- Start
- Oct 2003
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Valproate with Placebo (2 arms). Primary endpoint: Presence of Agitation and/or Psychosis Measured by the Neuropsychiatric Inventory (NPI) Combined With an Assessment of the Clinical Significance of Behavioral Change Rated by the Study Clinician at 24 months. Started Oct 2003; status: completed.
02
Drugs
valproic acid
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00071721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00071721.